- Home
- ZION vs RVMD Comparison
ZION vs RVMD Comparison
Compare ZION & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZION | RVMD |
|---|---|---|
| Founded | 1873 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4B | 15.2B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ZION | RVMD |
|---|---|---|
| Price | $53.21 | $94.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 20 | 16 |
| Target Price | $63.40 | ★ $114.63 |
| AVG Volume (30 Days) | ★ 1.7M | 1.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.32% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.39 | N/A |
| Revenue Next Year | $4.65 | $454.85 |
| P/E Ratio | $10.32 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $39.32 | $29.17 |
| 52 Week High | $66.18 | $124.49 |
Technical Indicators
Market Signals| Indicator | ZION | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 30.28 | 39.16 |
| Support Level | $46.34 | $93.59 |
| Resistance Level | $53.90 | $107.45 |
| Average True Range (ATR) | 1.70 | 3.80 |
| MACD | -0.61 | -0.82 |
| Stochastic Oscillator | 1.60 | 1.39 |
Price Performance
Historical ComparisonAbout ZION Zions Bancorporation N.A.
Zions Bancorp is a US regional bank with around $90 billion in total assets as of Sept. 30, 2025. Headquartered in Salt Lake City, Utah, Zions' branch network is in the Western and Southwestern United States and includes seven affiliate banks in these markets. The bank has a heavy focus on small and midsize commercial banking.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.